• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Impact of Safety Profiles on BTK Inhibitor Selection in R/R CLL

Opinion
Video

Panelists discuss how distinct safety profiles among Bruton tyrosine kinase (BTK) inhibitors—including variations in cardiovascular effects, bleeding risk, infection susceptibility, and other adverse events—guide personalized treatment decisions in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) based on individual comorbidities and risk factors.

Related Videos
Dr Chun Chao
3 experts are featured in this series.
2 experts in this video
Dr Chun Chao
1 expert is featured in this series.
Dr Chun Chao
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.